YU70201A - Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja - Google Patents

Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja

Info

Publication number
YU70201A
YU70201A YU70201A YUP70201A YU70201A YU 70201 A YU70201 A YU 70201A YU 70201 A YU70201 A YU 70201A YU P70201 A YUP70201 A YU P70201A YU 70201 A YU70201 A YU 70201A
Authority
YU
Yugoslavia
Prior art keywords
carnitine
esters
active compounds
pharmacologically active
carnatines
Prior art date
Application number
YU70201A
Other languages
English (en)
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciano Critelli
Giovanni Salvatori
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority to MEP-240/08A priority Critical patent/MEP24008A/xx
Publication of YU70201A publication Critical patent/YU70201A/sh
Publication of RS50911B publication Critical patent/RS50911B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Opisani su estri L-karnitina i alkanoil L-kamitina koji se mogu koristiti kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja. Takodje, opisani su novi estri L-karnitina i alkanoil L-karnitina formule (I) gde su grupe R definisane u opisu.
YUP-702/01A 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja RS50911B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-240/08A MEP24008A (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti

Publications (2)

Publication Number Publication Date
YU70201A true YU70201A (sh) 2004-07-15
RS50911B RS50911B (sr) 2010-08-31

Family

ID=11406659

Country Status (34)

Country Link
US (4) US6797281B1 (sh)
EP (3) EP1426044B1 (sh)
JP (2) JP4703855B2 (sh)
KR (2) KR100684378B1 (sh)
CN (2) CN1263730C (sh)
AT (2) ATE286873T1 (sh)
AU (2) AU776301B2 (sh)
BG (3) BG65501B1 (sh)
BR (2) BR0009765B1 (sh)
CA (2) CA2650202C (sh)
CZ (1) CZ302628B6 (sh)
DE (2) DE60025961T2 (sh)
DK (2) DK1183228T3 (sh)
EA (2) EA006021B1 (sh)
EE (2) EE05719B1 (sh)
ES (2) ES2234591T3 (sh)
HK (2) HK1045145B (sh)
HR (1) HRP20010740B1 (sh)
HU (1) HU229366B1 (sh)
IL (4) IL145765A0 (sh)
IS (2) IS2476B (sh)
IT (1) IT1306129B1 (sh)
ME (2) MEP24008A (sh)
MX (1) MXPA01010359A (sh)
NO (2) NO327742B1 (sh)
NZ (2) NZ515270A (sh)
PL (2) PL204418B1 (sh)
PT (2) PT1426044E (sh)
RS (3) RS20090448A (sh)
SI (2) SI1426044T1 (sh)
SK (2) SK288246B6 (sh)
TR (2) TR200102941T2 (sh)
WO (1) WO2000061543A2 (sh)
ZA (1) ZA200109291B (sh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
DE10113446A1 (de) 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
DK2108362T3 (da) * 2002-06-26 2013-09-02 Medigene Ag Kationisk liposomal-fremstilling omfattende en taxan
DK2286795T3 (en) * 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CA2617873A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
BRPI0614757A2 (pt) * 2005-08-10 2011-04-12 Novartis Ag composição farmacêutica, micropartìcula e seu uso
US20100178325A1 (en) * 2006-08-23 2010-07-15 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
JP2010518012A (ja) * 2007-02-01 2010-05-27 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ カンプトテシン誘導体を含む医薬組成物
US20100104625A1 (en) * 2007-02-16 2010-04-29 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) * 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
JP4827986B2 (ja) 2007-06-08 2011-11-30 マンカインド コーポレ−ション IRE−1αインヒビター
AU2009223222A1 (en) 2008-03-13 2009-09-17 Perkinelmer Health Sciences, Inc. Enzymatic substrates for multiple detection systems
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2014145418A1 (en) 2013-03-15 2014-09-18 Perkinelmer Health Sciences, Inc. Compounds and methods relating to testing for lysosomal storage disorders
KR20180114946A (ko) 2016-03-02 2018-10-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 sting 활성화 나노백신
US11103588B2 (en) 2017-06-06 2021-08-31 Wayne State University Methods and compositions relating to carnitine-derived materials
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
JPH05507929A (ja) * 1990-06-15 1993-11-11 ウェイク フォレスト ユニバーシティー エーテル脂質―ヌクレオシド共有結合体
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
EP0706374B1 (en) * 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
AU707734B2 (en) * 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
US6294378B1 (en) * 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
EP1426044B1 (en) 2006-02-08
SI1426044T1 (sl) 2006-04-30
SK287253B6 (sk) 2010-04-07
EE201100028A (et) 2011-08-15
IS2539B (is) 2009-09-15
IL185486A0 (en) 2008-01-06
IS6095A (is) 2001-09-28
SK14312001A3 (sk) 2002-02-05
CA2650202C (en) 2012-12-11
AU4312300A (en) 2000-11-14
PL211710B1 (pl) 2012-06-29
BR0009765A (pt) 2002-01-02
HU229366B1 (en) 2013-11-28
TR200202358T2 (tr) 2002-12-23
SK288246B6 (sk) 2015-03-03
EE200100518A (et) 2002-12-16
US7585519B2 (en) 2009-09-08
EA200300745A1 (ru) 2003-12-25
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
CN100402017C (zh) 2008-07-16
HK1045145B (zh) 2006-01-27
NZ528874A (en) 2005-09-30
CA2370143A1 (en) 2000-10-19
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
IS2476B (is) 2008-12-15
HUP0201446A2 (en) 2002-08-28
CA2370143C (en) 2011-06-21
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
NO20014985L (no) 2001-10-12
HUP0201446A3 (en) 2002-11-28
PT1183228E (pt) 2005-04-29
CN1823731A (zh) 2006-08-30
ATE317257T1 (de) 2006-02-15
DE60017388D1 (de) 2005-02-17
IL145765A (en) 2007-07-04
ES2258688T3 (es) 2006-09-01
US20050079209A1 (en) 2005-04-14
WO2000061543A3 (en) 2001-01-11
EP1426044A1 (en) 2004-06-09
BG109876A (en) 2008-02-29
US20070190128A1 (en) 2007-08-16
TR200102941T2 (tr) 2002-05-21
EE05514B1 (et) 2012-02-15
IL145765A0 (en) 2002-07-25
PT1426044E (pt) 2006-06-30
RS20090448A (en) 2010-06-30
JP4703855B2 (ja) 2011-06-15
SI1183228T1 (en) 2005-04-30
DE60025961T2 (de) 2006-08-17
BR0009765B1 (pt) 2013-11-05
MEP24008A (en) 2010-06-10
HRP20010740B1 (en) 2005-08-31
ZA200109291B (en) 2002-08-16
CA2650202A1 (en) 2000-10-19
AU776301B2 (en) 2004-09-02
AU2004224958B2 (en) 2007-11-22
DK1183228T3 (da) 2005-05-17
EA004459B1 (ru) 2004-04-29
EP1435232A1 (en) 2004-07-07
BG65312B1 (bg) 2008-01-31
IS8719A (is) 2008-03-07
ME00113B (me) 2010-10-10
RS50911B (sr) 2010-08-31
AU2004224958A1 (en) 2004-11-25
US6797281B1 (en) 2004-09-28
EP1183228B1 (en) 2005-01-12
EE05719B1 (et) 2014-08-15
DE60025961D1 (de) 2006-04-20
US7629003B2 (en) 2009-12-08
JP5420507B2 (ja) 2014-02-19
BG105971A (en) 2002-08-30
EP1183228A2 (en) 2002-03-06
NO20014985D0 (no) 2001-10-12
KR20010113794A (ko) 2001-12-28
KR20060113799A (ko) 2006-11-02
IT1306129B1 (it) 2001-05-30
DK1426044T3 (da) 2006-06-12
KR100798499B1 (ko) 2008-01-28
CZ20013617A3 (cs) 2002-02-13
NO327742B1 (no) 2009-09-14
BG65501B1 (bg) 2008-10-31
JP2011042657A (ja) 2011-03-03
BRPI0017460B1 (pt) 2016-04-19
CN1359370A (zh) 2002-07-17
HRP20010740A2 (en) 2002-10-31
CN1263730C (zh) 2006-07-12
ATE286873T1 (de) 2005-01-15
EA006021B1 (ru) 2005-08-25
NO20085413L (no) 2001-10-12
NO336949B1 (no) 2015-11-30
IL175366A0 (en) 2006-09-05
ES2234591T3 (es) 2005-07-01
KR100684378B1 (ko) 2007-02-20
IL175366A (en) 2010-12-30
PL204418B1 (pl) 2010-01-29
JP2002541238A (ja) 2002-12-03
ITRM990220A1 (it) 2000-10-13
DE60017388T2 (de) 2006-03-30
HK1092732A1 (en) 2007-02-16
CZ302628B6 (cs) 2011-08-10
EA200101076A1 (ru) 2002-04-25
HK1045145A1 (en) 2002-11-15

Similar Documents

Publication Publication Date Title
YU70201A (sh) Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
AU2274201A (en) Compounds and compositions for delivering active agents
RS50035B (sr) Farmaceutska kompozicija koja sadrži fenofibrat i postupak za njeno dobijanje
SE9904505D0 (sv) Novel compounds
NO20013700D0 (no) GCSF-konjugater
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
AU2845599A (en) Pharmaceutical compositions and their use
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
BR0111678A (pt) Composições medicinais contendo derivados de propenona
BE1014502A5 (fr) Compositions pharmaceutiques.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
MY139010A (en) 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives
SE0302924D0 (sv) Pharmaceutical composition having a cationic excipient
HK1042300A1 (en) Polycyclic thiazole systems and their utilization as anorectics.
PT1244614E (pt) Inibidores de triptase
AU6832498A (en) Substituted benzyl oximino compounds
DE60003074D1 (de) Fusidinsäure-derivate
DK1173065T3 (da) Anvendelse af cellulosemikrofibriller i fermenterede mælkepræparater
DE69918974D1 (de) Perfluorierte ester von alkanoyl l-carnitin zur herstellung von kationischen lipiden zur intrazellulären verabreichung pharmakologisch aktiver verbindungen